Emergent BioSolutions (EBS) Stock Forecast & Price Target

Emergent BioSolutions is viewed positively because it is actively strengthening its balance sheet, having repurchased $75 million of 3.875% senior unsecured notes and reduced outstanding debt to about $515 million while still maintaining expected cash and cash equivalents above $180 million and access to an additional $50 million revolver. Its operating outlook is also supported by resilient government-backed demand, including a ~$24 million BARDA anthrax vaccine contract modification and 2Q26 revenue growth in anthrax MCM products of 6% and smallpox MCM products of 150%, reflecting strong demand for countermeasures. Management is further improving efficiency through a restructuring expected to generate about $40 million in annualized cost savings, while new NARCAN, ACAM2000, and international approvals broaden commercial momentum and diversify growth drivers.

Emergent BioSolutions is facing a deteriorating fundamental outlook as 2Q26 revenue of $234.3M beat expectations, yet management cut full-year 2026 revenue guidance to $645M-$675M from $720M-$760M, signaling weaker visibility ahead. The primary pressure point is the naloxone franchise, where NARCAN sales fell 22% year over year in 2Q26 on unfavorable U.S. price-volume mix, and newly approved OTC competitors REXTOVY on June 16, 2026 and REZENOPY are likely to intensify erosion. Although Canadian branded NARCAN and KLOXXADO provided some offset, the company’s dependence on a shrinking U.S. public-interest channel and reduced 2027 revenue expectations to $810M from $892M underscore a negative outlook.